National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 18 years or older.
Able to provide informed consent.
Pre-treatment diagnosis of obesity (BMI≥30kg/m2).
On a high potency GLP-1 based therapy (defined as semaglutide ≥1.7 mg or tirzepatide≥10mg).
Has achieved, or are close to achieving, a "target body weight." Target body weight will be defined by each individual patient through self-report or their treating clinician but should generally be at least 5% below their weight prior to first starting GLP-1 based therapy.
Has been on an incretin-based weight loss therapy for at least 6 months.
You may not be if
Diagnosis of type 2 diabetes or pre-existing cardiovascular disease.
Pregnancy or nursing or are seeking to become pregnant in the next year.
Have had bariatric surgery.
Unwilling to reduce the dose of their GLP-1 medication for weight loss, or who are unwilling to switch to another non-GLP-1based weight loss medication.
Contraindications to bupropion/naltrexone: chronic opioid use, seizure disorders, use of other bupropion containing products, uncontrolled hypertension, monoamine oxidase inhibitors.
Hyperthyroidism.
Glaucoma, or at risk for glaucoma.
History of substance use disorder.
History of suicidal ideation.
Concomitant monoamine oxidase inhibitors within 14 days.
Use of lithium.
Use of metformin.
Clareo Health | Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s
